Amryt Pharma plc
Index- P/E- EPS (ttm)-0.09 Insider Own0.08% Shs Outstand64.05M Perf Week0.07%
Market Cap619.53M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float29.82M Perf Month-0.34%
Income-0.80M PEG- EPS next Q-0.04 Inst Own75.80% Short Float / Ratio0.41% / 0.16 Perf Quarter99.73%
Sales243.60M P/S2.54 EPS this Y100.50% Inst Trans0.65% Short Interest0.12M Perf Half Y104.78%
Book/sh5.06 P/B2.88 EPS next Y75.00% ROA-0.10% Target Price17.50 Perf Year82.00%
Cash/sh1.96 P/C7.44 EPS next 5Y- ROE-0.20% 52W Range6.41 - 14.77 Perf YTD99.45%
Dividend- P/FCF5.81 EPS past 5Y15.10% ROI-5.50% 52W High-1.42% Beta-
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin47.90% 52W Low127.15% ATR0.06
Employees241 Current Ratio1.60 Sales Q/Q8.10% Oper. Margin-19.80% RSI (14)59.59 Volatility0.24% 0.30%
OptionableYes Debt/Eq0.66 EPS Q/Q0.20% Profit Margin-0.30% Rel Volume0.00 Prev Close14.56
ShortableYes LT Debt/Eq0.65 Earnings- Payout0.00% Avg Volume736.87K Price14.56
Recom2.70 SMA20-0.14% SMA50-0.32% SMA20055.83% Volume0 Change0.00%
Sep-06-22Resumed Canaccord Genuity Buy $19
Aug-19-21Initiated SVB Leerink Outperform $22
Aug-19-21Initiated Cowen Outperform $22
Jul-27-21Initiated H.C. Wainwright Buy $29
Mar-22-23 11:00AM
Feb-16-23 07:00AM
Jan-08-23 03:00PM
Jan-05-23 07:00AM
Dec-19-22 07:00AM
07:00AM Loading…
Dec-05-22 07:00AM
Nov-30-22 07:00AM
Nov-03-22 07:00AM
Oct-31-22 07:00AM
Oct-25-22 07:00AM
Oct-24-22 07:00AM
Oct-19-22 07:00AM
Oct-18-22 07:00AM
Oct-17-22 07:00AM
Sep-23-22 07:00AM
07:30AM Loading…
Sep-16-22 07:30AM
Sep-13-22 07:00AM
Sep-08-22 07:00AM
Sep-07-22 07:00AM
Aug-04-22 07:00AM
Jul-21-22 07:00AM
Jul-14-22 07:00AM
Jul-07-22 07:00AM
Jul-01-22 07:00AM
Jun-27-22 07:00AM
Jun-24-22 07:00AM
Jun-23-22 07:00AM
Jun-13-22 08:00AM
Jun-08-22 07:00AM
Jun-01-22 07:00AM
07:00AM Loading…
May-17-22 07:00AM
May-11-22 07:00AM
May-04-22 07:00AM
Apr-22-22 10:15AM
Apr-14-22 07:00AM
Apr-13-22 07:00AM
Mar-31-22 07:00AM
Mar-26-22 11:00AM
Mar-08-22 07:00AM
Mar-03-22 09:18AM
Mar-02-22 03:00PM
Feb-28-22 09:15AM
Feb-25-22 07:00AM
Feb-23-22 07:00AM
Feb-22-22 07:00AM
Feb-01-22 07:00AM
Jan-28-22 07:00AM
Jan-18-22 07:37AM
Jan-11-22 07:00AM
Jan-06-22 02:00AM
Jan-04-22 07:00AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-11-21 11:59AM
Dec-10-21 09:38PM
Dec-01-21 02:00AM
Nov-30-21 02:00AM
Nov-24-21 10:31AM
Nov-23-21 07:00AM
Nov-22-21 02:00AM
Nov-03-21 08:35AM
Nov-01-21 09:00AM
Oct-28-21 03:06PM
Oct-20-21 07:00AM
Oct-19-21 07:00AM
Oct-14-21 06:57AM
Oct-01-21 02:00AM
Sep-27-21 11:55AM
Sep-13-21 07:00AM
Sep-01-21 02:00AM
Aug-19-21 02:00AM
Aug-10-21 09:20AM
Aug-09-21 07:00AM
Aug-06-21 07:00AM
Aug-05-21 10:50AM
Jul-28-21 10:00AM
Jul-12-21 07:00AM
Jun-28-21 07:00AM
Jun-15-21 06:45AM
Jun-10-21 09:32AM
Jun-07-21 07:00AM
Jun-04-21 09:35AM
Jun-03-21 08:07AM
Jun-02-21 08:30AM
May-06-21 03:54PM
May-05-21 05:36PM
Apr-17-21 09:20AM
Apr-15-21 07:00AM
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.